Fentanyl Lavipharm
Transdermal patch – Strong opioid analgesic for severe chronic pain
Quick Facts About Fentanyl Lavipharm
Key Takeaways About Fentanyl Lavipharm
- Only for opioid-tolerant patients: Fentanyl Lavipharm must never be used by patients who have not been taking opioids regularly, as it can cause fatal respiratory depression
- 72-hour continuous pain relief: Each transdermal patch delivers fentanyl steadily through the skin for 3 days before needing replacement
- Avoid heat exposure: Heat sources (saunas, heating pads, hot baths, fever) can dramatically increase fentanyl absorption and cause life-threatening overdose
- Safe disposal is critical: Used patches still contain significant amounts of fentanyl and must be folded and disposed of safely to prevent accidental exposure, especially in children
- Drug interactions are dangerous: Combining fentanyl with benzodiazepines, alcohol, or other CNS depressants greatly increases the risk of fatal respiratory depression
What Is Fentanyl Lavipharm and What Is It Used For?
Fentanyl Lavipharm is a transdermal patch that delivers the potent synthetic opioid fentanyl through the skin to manage severe, persistent pain. It is indicated for adults and children aged 2 years and older who are already opioid-tolerant and require continuous, around-the-clock opioid analgesia that cannot be adequately managed with alternative treatments.
Fentanyl belongs to the phenylpiperidine class of synthetic opioid analgesics and is approximately 80 to 100 times more potent than morphine on a milligram-per-milligram basis. Unlike immediate-release opioid formulations, the Fentanyl Lavipharm transdermal system is designed to provide a controlled, steady release of the active substance through the skin and into the systemic circulation over a period of 72 hours. This continuous delivery helps maintain stable blood levels, reducing the peaks and troughs that are often associated with oral opioid dosing and that can contribute to breakthrough pain or side effects.
The primary indications for Fentanyl Lavipharm include the management of severe cancer-related pain and severe chronic non-cancer pain. According to the World Health Organization (WHO) analgesic ladder, strong opioids such as fentanyl are recommended as step-three therapy for patients whose pain is not adequately controlled by non-opioid analgesics and weaker opioids. The European Society for Medical Oncology (ESMO) guidelines similarly recommend transdermal fentanyl as a first-line option for patients with stable, severe cancer pain who prefer or require a non-oral route of administration.
It is critically important to understand that Fentanyl Lavipharm is not appropriate for acute pain, post-operative pain, or intermittent pain. The slow onset of action (12–24 hours to reach therapeutic blood levels) means it cannot provide rapid pain relief. Additionally, starting fentanyl patches in opioid-naive patients – those who have not been taking opioid medications regularly – can lead to life-threatening or fatal respiratory depression. The prescribing of Fentanyl Lavipharm should always be initiated by a physician experienced in the management of chronic pain with strong opioids.
Fentanyl Lavipharm must ONLY be prescribed to patients who are already opioid-tolerant. Opioid-tolerant patients are those who have been taking, for a week or longer, at least 60 mg of oral morphine daily, 25 mcg of transdermal fentanyl per hour, 30 mg of oral oxycodone daily, 8 mg of oral hydromorphone daily, or an equianalgesic dose of another opioid. Using this patch in non-opioid-tolerant patients may result in fatal respiratory depression.
How Does Fentanyl Work?
Fentanyl exerts its analgesic effects primarily by binding to mu-opioid receptors (MOR) in the central nervous system, particularly in the brain and spinal cord. When fentanyl binds to these receptors, it activates descending inhibitory pain pathways and alters the perception of, and emotional response to, pain. The high lipophilicity (fat solubility) of fentanyl is what makes it particularly suitable for transdermal delivery, as it can readily pass through the skin and into the bloodstream.
After application of the patch, fentanyl is absorbed from the skin into the subcutaneous fat layer, which serves as a drug reservoir. The drug then gradually enters the systemic circulation. Peak plasma concentrations are typically reached within 24 to 72 hours after the first application, and steady-state levels are achieved after two sequential 72-hour applications. When the patch is removed, serum fentanyl levels decline gradually over approximately 17 hours or more, owing to the continued absorption of fentanyl from the skin depot.
What Should You Know Before Taking Fentanyl Lavipharm?
Before starting Fentanyl Lavipharm, it is essential to ensure you are opioid-tolerant, to disclose all current medications, and to understand the serious risks including respiratory depression, dependence, and life-threatening interactions with alcohol and CNS depressants.
Contraindications
Fentanyl Lavipharm must not be used in certain situations. Absolute contraindications include:
- Opioid-naive patients: Patients who are not currently taking opioid medications on a regular basis must never use fentanyl patches due to the risk of fatal respiratory depression
- Hypersensitivity: Known allergy to fentanyl or any of the patch components (adhesives, backing film)
- Severe respiratory depression: Patients with significant respiratory compromise or severe bronchial asthma in an unmonitored setting
- Severe obstructive airway disease: Including severe chronic obstructive pulmonary disease (COPD)
- Acute or post-operative pain: The slow onset of action makes fentanyl patches unsuitable for short-term or acute pain management
- Paralytic ileus: Known or suspected gastrointestinal obstruction
Warnings and Precautions
Several important warnings apply to the use of Fentanyl Lavipharm. Patients and healthcare providers should be aware of the following precautions:
Respiratory depression is the most serious risk associated with fentanyl. It can occur at any time during therapy, but the risk is greatest during initiation and dose escalation. Patients should be monitored closely, especially during the first 24 to 72 hours after starting therapy or increasing the dose. The risk is substantially increased when fentanyl is combined with benzodiazepines, other sedatives, alcohol, or other CNS depressants.
Heat exposure can cause a significant and potentially dangerous increase in fentanyl absorption. Patients must avoid exposing the patch application site to direct external heat sources such as heating pads, electric blankets, heated waterbeds, heat lamps, saunas, hot tubs, and prolonged direct sunlight. Fever can also increase fentanyl absorption, and patients with high body temperature should be monitored for opioid toxicity and dose adjustments may be necessary.
Accidental exposure to fentanyl patches, particularly in children, can be fatal. Patches must be stored securely, applied properly so they do not dislodge, and disposed of carefully. Used patches still contain significant residual fentanyl. The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both issued safety alerts regarding accidental fentanyl exposure in children.
Physical dependence and tolerance develop with prolonged use of all opioids, including fentanyl. Abrupt discontinuation can precipitate withdrawal symptoms including restlessness, lacrimation, rhinorrhoea, yawning, perspiration, chills, myalgia, and mydriasis. The dose should always be tapered gradually under medical supervision rather than stopped suddenly.
Use with caution and closer monitoring in patients with: head injuries or increased intracranial pressure, hepatic or renal impairment, bradyarrhythmias, hypotension, hypovolaemia, myasthenia gravis, or elderly or cachectic (very underweight) patients. These conditions may increase the risk or severity of side effects.
Pregnancy and Breastfeeding
Fentanyl Lavipharm should only be used during pregnancy if the potential benefit justifies the potential risk to the foetus. Prolonged use of opioids during pregnancy can cause neonatal opioid withdrawal syndrome (NOWS), which can be life-threatening if not recognised and treated promptly. Symptoms in newborns include irritability, hyperactivity, abnormal sleep pattern, high-pitched crying, tremor, vomiting, diarrhoea, and failure to gain weight.
Fentanyl is excreted in human breast milk and may cause sedation and respiratory depression in a nursing infant. Breastfeeding is generally not recommended during treatment with Fentanyl Lavipharm and for at least 72 hours after removal of the last patch. Women of childbearing potential should use effective contraception during treatment, as advised by the EMA product information.
How Does Fentanyl Lavipharm Interact with Other Drugs?
Fentanyl Lavipharm can have potentially life-threatening interactions with several drug classes, most notably CNS depressants (including benzodiazepines and alcohol), CYP3A4 inhibitors that increase fentanyl levels, and serotonergic drugs that may cause serotonin syndrome.
Drug interactions with fentanyl can lead to severe adverse outcomes including fatal respiratory depression, profound sedation, serotonin syndrome, or reduced analgesic efficacy. It is essential that prescribers review all of a patient's current medications, including over-the-counter products and herbal supplements, before initiating Fentanyl Lavipharm. Patients should always inform their healthcare provider or pharmacist about any new medications they begin taking while using the patch.
Major Interactions
| Interacting Drug/Class | Effect | Clinical Significance |
|---|---|---|
| Benzodiazepines (diazepam, alprazolam, lorazepam) | Profound sedation, respiratory depression, coma, death | FDA boxed warning – avoid concurrent use unless no alternative |
| Alcohol | Increased CNS depression, risk of fatal respiratory arrest | Strictly contraindicated during treatment |
| CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin, erythromycin, grapefruit juice) | Increased fentanyl plasma levels, risk of fatal overdose | Monitor closely; dose reduction may be required |
| MAO inhibitors (phenelzine, tranylcypromine, selegiline) | Unpredictable potentiation of opioid effects, serotonin syndrome risk | Avoid use within 14 days of MAO inhibitor therapy |
| Serotonergic drugs (SSRIs, SNRIs, triptans, tramadol, St. John's Wort) | Serotonin syndrome (agitation, hallucinations, hyperthermia, tachycardia) | Monitor for symptoms; discontinue if serotonin syndrome suspected |
| Other CNS depressants (sedating antihistamines, general anaesthetics, phenothiazines, gabapentinoids, muscle relaxants) | Additive respiratory depression and sedation | Use lowest effective doses; enhanced monitoring required |
Minor Interactions
| Interacting Drug/Class | Effect | Clinical Significance |
|---|---|---|
| CYP3A4 inducers (rifampicin, carbamazepine, phenytoin, phenobarbital) | Decreased fentanyl plasma levels, reduced analgesic effect | May need dose increase; monitor pain control |
| Mixed agonists/antagonists (buprenorphine, nalbuphine, pentazocine) | May reduce analgesic effect; may precipitate withdrawal | Avoid concurrent use |
| Anticholinergic drugs | Increased risk of urinary retention and severe constipation; may lead to paralytic ileus | Monitor bowel function and urinary output |
| Diuretics | Opioids may reduce efficacy of diuretics via ADH release | Monitor fluid balance |
What Is the Correct Dosage of Fentanyl Lavipharm?
The dosage of Fentanyl Lavipharm must be individualised based on the patient's prior opioid exposure, current pain intensity, and overall clinical status. The lowest effective dose should always be used. The starting dose for opioid-tolerant adults is typically 25 mcg/h, with dose adjustments made no more frequently than every 72 hours.
Dosing of Fentanyl Lavipharm requires careful calculation based on the patient's current opioid regimen. Equianalgesic conversion tables should be used to determine the appropriate starting dose. It is generally recommended to underestimate the initial dose and provide supplemental short-acting opioids for breakthrough pain rather than overestimating and risking overdose. The following sections outline dosing guidelines by patient group.
Adults
Adult Dosing Guidelines
For opioid-tolerant adults, the initial dose is determined by converting the current 24-hour opioid requirement to an equivalent transdermal fentanyl dose using established equianalgesic tables. Common starting doses and their approximate oral morphine equivalents are shown below:
| Oral Morphine (24h) | Fentanyl Patch Dose | Patch Change |
|---|---|---|
| 60–89 mg/day | 25 mcg/h | Every 72 hours |
| 90–149 mg/day | 50 mcg/h | Every 72 hours |
| 150–209 mg/day | 75 mcg/h | Every 72 hours |
| 210–269 mg/day | 100 mcg/h | Every 72 hours |
Dose titration should be performed in increments of 12 or 25 mcg/h, no more frequently than every 72 hours after the initial application, or every 6 days thereafter. Patients should have access to short-acting analgesics for breakthrough pain during dose titration. If the patient requires more than two doses of supplemental analgesic per day for more than three consecutive days, the fentanyl patch dose should be increased.
Children (Aged 2 Years and Older)
Fentanyl Lavipharm may be used in opioid-tolerant children aged 2 years and older who are receiving at least 30 mg of oral morphine equivalent per day. Paediatric dosing must be calculated carefully by converting the child's current opioid dose using conservative equianalgesic conversion ratios. The lowest available patch strength (12 mcg/h) should be considered for children converting from low-dose opioid therapy. Children should be monitored closely by caregivers and healthcare providers, especially during the first 72 hours of therapy.
Fentanyl Lavipharm is contraindicated in children under 2 years of age due to the increased risk of life-threatening respiratory depression and the lack of adequate safety data in this age group.
Elderly Patients
Elderly patients may be more sensitive to the effects of fentanyl due to age-related changes in pharmacokinetics, including reduced clearance, decreased lean body mass, and altered distribution. The National Institute for Health and Care Excellence (NICE) recommends starting with the lowest available dose and titrating slowly while monitoring for excessive sedation and respiratory depression. Elderly patients with renal or hepatic impairment require particularly cautious dosing, as fentanyl metabolites may accumulate.
Missed Dose
If a patch falls off before the 72-hour period has elapsed, a new patch should be applied to a different skin site immediately. If a scheduled patch change is missed, the patient should apply a new patch as soon as they remember and resume the regular schedule from that point. The old patch should be removed and folded over on itself before safe disposal. Patients should never apply two patches simultaneously to make up for a missed dose unless instructed by their prescriber.
Overdose
Fentanyl overdose is a medical emergency. The primary symptom is respiratory depression (slow, shallow, or stopped breathing). Other signs include extreme drowsiness, inability to think, talk, or walk normally, feeling faint, dizziness, confusion, and pinpoint pupils. In severe cases, circulatory collapse, cardiac arrest, and death may occur.
Immediate actions: Remove the patch immediately. Call emergency services. If available, administer naloxone (Narcan) – the opioid reversal agent. Note that because fentanyl is long-acting in patch form, repeated doses of naloxone may be necessary as the duration of opioid reversal may be shorter than the duration of fentanyl's effect. Maintain airway, breathing, and circulation until emergency help arrives.
What Are the Side Effects of Fentanyl Lavipharm?
Like all opioid medications, Fentanyl Lavipharm can cause side effects. The most common include nausea, constipation, drowsiness, and dizziness. The most serious potential side effect is respiratory depression, which can be fatal. Most side effects are dose-dependent and may diminish as tolerance develops.
Side effects from fentanyl transdermal patches are generally consistent with those expected from opioid therapy. They are usually most pronounced during the initiation of treatment and after dose increases, and tend to decrease in intensity as the body adapts. However, constipation typically persists throughout therapy and should be managed proactively with laxatives. The following classification is based on frequency data from clinical trials and post-marketing surveillance as reported by the EMA and FDA.
Very Common (affects more than 1 in 10 patients)
- Nausea
- Constipation
- Drowsiness / somnolence
- Dizziness
- Headache
Common (affects 1 to 10 in 100 patients)
- Vomiting
- Dry mouth
- Abdominal pain
- Loss of appetite (anorexia)
- Fatigue and asthenia (weakness)
- Pruritus (itching)
- Excessive sweating (hyperhidrosis)
- Skin reactions at application site (redness, rash, itching)
- Insomnia
- Anxiety and depression
- Confusion and disorientation
- Tremor
- Dyspnoea (shortness of breath)
- Urinary retention
- Oedema (swelling)
Uncommon (affects 1 to 10 in 1,000 patients)
- Hallucinations and delirium
- Agitation and euphoria
- Muscle twitching (myoclonus)
- Paraesthesia (tingling, numbness)
- Speech disorder
- Tachycardia (rapid heart rate)
- Bradycardia (slow heart rate)
- Hypotension (low blood pressure)
- Biliary colic
- Flatulence and diarrhoea
- Blurred vision
- Erectile dysfunction
Rare (affects fewer than 1 in 1,000 patients)
- Respiratory depression (potentially fatal)
- Apnoea (cessation of breathing)
- Seizures / convulsions
- Severe allergic / anaphylactic reaction
- Ileus (bowel obstruction)
- Serotonin syndrome (with concurrent serotonergic drugs)
- Adrenal insufficiency
- Androgen deficiency (with chronic use)
Contact emergency services immediately if you experience: very slow, shallow, or stopped breathing; extreme drowsiness or inability to stay awake; severe dizziness or fainting; seizures; severe allergic reaction (swelling of face, lips, tongue, difficulty breathing); or skin turning blue or grey (cyanosis). These may be signs of life-threatening complications.
How Should You Store Fentanyl Lavipharm?
Store Fentanyl Lavipharm patches in their original sealed pouches at room temperature (below 25°C / 77°F) in a secure location out of the reach and sight of children. Do not use patches after the expiry date printed on the package.
Fentanyl Lavipharm patches should be stored at temperatures not exceeding 25°C (77°F). Keep the patches in their original sealed sachets until ready for use, as exposure to air can affect the adhesive properties and drug release characteristics. Do not store in the bathroom or near heat or moisture sources. The patches should be kept in a locked or secure storage area to prevent accidental access, theft, or misuse, particularly where children may be present.
Do not refrigerate or freeze fentanyl patches. Do not use a patch if the sealed sachet has been damaged, opened, or tampered with. Check the expiry date before each application and do not use expired patches. Return unused or expired patches to a pharmacy for safe disposal through a take-back programme.
Safe Disposal of Used Patches
Used fentanyl patches still contain a significant amount of residual fentanyl – enough to be harmful or fatal, particularly to children and pets. Immediately after removal, fold the used patch firmly in half with the sticky side inward so that the adhesive side sticks to itself. The safest method of disposal is to return used patches to a pharmacy. If this is not possible, the FDA recommends flushing used patches down the toilet. Never place used patches in household waste bins where they could be accessed by children, pets, or others.
Accidental exposure to fentanyl patches, especially in children, can result in respiratory depression and death. Even used patches contain enough fentanyl to cause serious harm. If a child or anyone who is not using fentanyl accidentally touches or applies a patch, remove the patch immediately, wash the area with water, and call emergency services or a poison control centre. Monitor the person for signs of breathing difficulty.
What Does Fentanyl Lavipharm Contain?
Each Fentanyl Lavipharm transdermal patch contains fentanyl as the active substance in varying strengths (12, 25, 50, 75, or 100 micrograms per hour). The patch also contains inactive ingredients including adhesive materials, a protective backing layer, and a release liner that is removed before application.
The active pharmaceutical ingredient in Fentanyl Lavipharm is fentanyl (as fentanyl base or fentanyl citrate, depending on the formulation). The total content of fentanyl in each patch varies by strength and is designed to deliver the labelled release rate over a 72-hour application period. The typical total fentanyl content per patch is as follows:
| Nominal Release Rate | Approximate Fentanyl Content | Patch Size |
|---|---|---|
| 12 mcg/h | ~2.1 mg | ~5.25 cm² |
| 25 mcg/h | ~4.2 mg | ~10.5 cm² |
| 50 mcg/h | ~8.4 mg | ~21.0 cm² |
| 75 mcg/h | ~12.6 mg | ~31.5 cm² |
| 100 mcg/h | ~16.8 mg | ~42.0 cm² |
The inactive components of the transdermal system typically include a backing layer (polyester film), an adhesive matrix containing the fentanyl (often a polyacrylate or silicone-based adhesive system), and a protective release liner that is removed prior to application. The specific excipients may vary between manufacturers and formulations. Patients with known sensitivities to adhesive materials should inform their healthcare provider, as skin reactions at the application site can occur.
How to Apply the Patch
Apply the patch to a flat, clean, dry, and hairless area of skin on the upper arm, chest, back, or upper leg. Do not apply the patch to irritated, broken, or damaged skin. Do not shave the area, as this can cause small cuts that alter absorption – if necessary, clip the hair with scissors instead. Press the patch firmly in place with the palm of your hand for at least 30 seconds, ensuring that the edges adhere properly. Wash your hands with water after handling the patch. When replacing a patch after 72 hours, apply the new patch to a different skin site to avoid irritation.
Frequently Asked Questions About Fentanyl Lavipharm
Fentanyl Lavipharm transdermal patches are used for the management of severe chronic pain that requires continuous, around-the-clock opioid treatment and cannot be managed by other pain medications. It is commonly prescribed for cancer-related pain and severe non-cancer chronic pain in patients who are already opioid-tolerant. It is not suitable for acute pain, post-operative pain, or intermittent pain.
Each Fentanyl Lavipharm transdermal patch is designed to be worn for 72 hours (3 days) before being replaced with a new patch on a different skin site. It takes approximately 12 to 24 hours after the first application to reach therapeutic blood levels, so short-acting pain relief may be needed during this initial period. Steady-state plasma levels are typically achieved after two consecutive 72-hour applications.
The most common side effects (affecting more than 1 in 10 patients) include nausea, constipation, drowsiness, dizziness, and headache. Other frequently reported effects include vomiting, dry mouth, loss of appetite, fatigue, itching, sweating, and skin reactions at the application site. Most side effects tend to decrease in intensity over time, with the notable exception of constipation, which typically persists and should be proactively managed with laxatives.
Yes, fentanyl patches can cause fatal overdose, particularly if used incorrectly. Never apply more patches than prescribed, never cut or damage patches, and avoid exposing the patch to external heat sources (heating pads, hot baths, saunas, direct sunlight) as this can dramatically increase fentanyl absorption. Signs of overdose include extreme drowsiness, slow or stopped breathing, pinpoint pupils, and loss of consciousness. In case of suspected overdose, remove the patch immediately and call emergency services. Naloxone (Narcan) can reverse opioid effects but may need to be given repeatedly.
Fentanyl Lavipharm should not be used by patients who are not already opioid-tolerant (i.e., those not regularly taking opioid medications), for acute or short-term pain, for mild-to-moderate pain, for post-operative pain, or by children under 2 years old. It is also contraindicated in patients with severe respiratory depression, severe obstructive airway disease, known hypersensitivity to fentanyl, or paralytic ileus. Patients with significant liver or kidney impairment require close monitoring and may need dose adjustments.
Used fentanyl patches still contain significant amounts of the drug and must be disposed of safely. Fold the used patch in half with the adhesive side inward and return it to a pharmacy for safe disposal. If a pharmacy take-back programme is not available, the FDA recommends flushing used patches down the toilet. Never place used patches in household waste where children or pets could access them. Accidental exposure to a used patch can cause serious harm or death, particularly in children.
References
- World Health Organization (WHO). WHO Guidelines for the Pharmacological and Radiotherapeutic Management of Cancer Pain in Adults and Adolescents. Geneva: WHO; 2018. Available from: who.int
- European Medicines Agency (EMA). Fentanyl Transdermal Patches – Summary of Product Characteristics. EMA; 2024. Available from: ema.europa.eu
- US Food and Drug Administration (FDA). Fentanyl Transdermal System – Prescribing Information and Medication Guide. FDA; 2024.
- National Institute for Health and Care Excellence (NICE). Palliative Care for Adults: Strong Opioids for Pain Relief. Clinical Guideline CG140. NICE; 2024. Available from: nice.org.uk
- Fallon M, Giusti R, Aielli F, et al. Management of Cancer Pain in Adult Patients: ESMO Clinical Practice Guidelines. Annals of Oncology. 2018;29(Suppl 4):iv166–iv191. DOI: 10.1093/annonc/mdy152
- Pergolizzi JV, Taylor R, LeQuang JA, Raffa RB. Managing Severe Chronic Pain: The Role of Transdermal Buprenorphine and Fentanyl. Current Medical Research and Opinion. 2020;36(3):517–528.
- British National Formulary (BNF). Fentanyl. NICE; 2025. Available from: bnf.nice.org.uk
- International Association for the Study of Pain (IASP). IASP Guidelines on the Use of Opioids in Chronic Non-Cancer Pain. IASP; 2023.
- Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC Clinical Practice Guideline for Prescribing Opioids for Pain – United States, 2022. MMWR Recomm Rep. 2022;71(No. RR-3):1–95.
- European Society for Medical Oncology (ESMO). Clinical Practice Guidelines: Cancer Pain Management. ESMO; 2024.
Editorial Team
This article was written, fact-checked, and medically reviewed by the iMedic Medical Editorial Team, which includes board-certified specialists in pain medicine, anaesthesiology, clinical pharmacology, and palliative care. All medical content follows the GRADE evidence framework and is based on current international guidelines from the WHO, EMA, FDA, NICE, and ESMO.
Every article undergoes a rigorous three-stage review: initial medical writing by qualified healthcare professionals, peer review by specialist physicians, and final editorial verification against current evidence-based guidelines.
We adhere to Evidence Level 1A standards, referencing systematic reviews, meta-analyses, and randomised controlled trials. All sources are from peer-reviewed journals and recognised international medical organisations.
For questions about our editorial process, contact us at our contact page. Learn more about our team at Medical Team.